A long recognised risk factor for breast cancer is a family history of the disease, although the majority of affected women do not have an affected close relative, and only 5--10% do have a true hereditary predisposition ([Carter, 2001](#bib1){ref-type="other"}). The overall risk of developing breast cancer is 1.9--3.9 times higher in women with an affected mother or sister ([Collaborative Group on Hormonal Factors in Breast Cancer, 2001](#bib3){ref-type="other"}), but only a few studies have investigated the characteristics of breast cancer in women with a family history. We analysed the pathological, biological and clinical features of breast cancer in patients with (FH+) and without (FH−) a family history of breast cancer, the former being further subdivided into those with an affected first- or second-degree relative.

MATERIALS AND METHODS
=====================

A total of 2256 women with early invasive operable breast cancer, who underwent surgery at Verona Hospitals between January 1992 and April 2001, were asked at their first visit whether they had any first- or second-degree relatives who had had breast cancer. Our analysis first compared those reporting at least one affected relative (FH+) with those reporting no affected relative (FH−); subsequently, the FH+ patients were divided into those with at least one first-degree relative (1st DFH) and those with only second-degree relatives with breast cancer (2nd DFH): only first- and second-degree relatives were considered in order to reduce ascertainment bias. Answers were always checked at the subsequent visit (at the time of the first cycle for the patients receiving chemotherapy, after 3 months for the others).

All of the patients were assigned a UICC pathological TNM stage. On the basis of pathologist-defined tumour size, patients were divided into three categories: pT1 (\<2 cm), pT2 (2--5 cm) and pT3 (\>5 cm); the number of pathologically positive axillary nodes was divided into none, \<3, 4--10 and \>10; tumour grading was recorded as G1 (well differentiated), G2 (moderately differentiated) or G3 (undifferentiated).

Immunohistochemistry (IHC) defined oestrogen (ER) and progesterone receptor (PgR) status and was considered positive if more than 10% of the cells were stained for either. The replicative cell fraction was IHC stained using the Ki-67 monoclonal antibody (Mab-DAKO-PC); given the lack of an accepted cutoff point, the results were arbitrarily classified as low, medium or high (⩽10%, 11--25% or \>25% of stained cells). C-*erb*B-2 levels were determined by IHC using the DAKO-PC monoclonal antibody, and considered positive if at least one cell was stained.

At their first visit to the Department of Medical Oncology, all patients were asked about their disease presentation and divided into those who underwent mammography and ultrasonography because of breast discomfort or a lump (symptomatic) and those without any subjective symptoms (asymptomatic). A public screening programme has been active in Verona since July 1999, before which 30% of our patients had undergone mammography and ultrasonography even in the absence of subjective symptoms.

For the analysis of the pathological, biological and clinical differences by age at diagnosis, the patients were arbitrarily divided into seven age groups (\<35, 36--45, 46--55, 56--65, 66--75, 76--85 and \>85 years).

The *χ*^2^ test was used to compare the prevalence of FH+ (1st and 2nd DFH) and FH− women in relation to all the variables.

As it is known that younger women have a higher risk associated with a family history, an age-adjusted analysis was made to compare the prevalence of FH+ women across the categories of the other considered variables.

Significance was tested using the likelihood ratio statistic and a significance level of 0.05.

RESULTS
=======

The overall prevalence of FH+ women was 30.7% (692), of whom, 356 (51.4%) were classified as 1st DFH and 336 (48.6%) as 2nd DFH. [Table 1](#tbl1){ref-type="table"} Table 1Correlation between breast cancer characteristics in patients with and without FH    ***P-*value*P-*value** **FH− no.^a^FH+ (1st degree) no.^b^FH+/total %RawAdjusted^c^***pTumour size*   0.0060.012 T11036502 (262)32.6   T2495173 (85)25.9   T33317 (9)34.0        *No. of positive nodes*   \>0.5\>0.5 0947412 (205)30.3   1--3360159 (82)30.6   4--1013566 (31)32.8   \>106327 (14)30.0        *ER*   0.0210.006 Negative28499 (48)25.8   Positive1199561 (288)31.9        *PgR*   0.2110.264 Negative511222 (104)30.3   Positive799394 (206)33.0        *Proliferative index*   0.1050.073 Ki-67=0--15%828400 (205)32.6   Ki-67=16--25%311140 (74)31.0   Ki-67=26--100%276101 (47)26.8        *Grading*   0.4760.397 G116579 (39)32.4   G2691320 (168)31.7   G336915028.9        *C-erb B2 status*   0.1070.065 Negative427239 (117)35.9   Positive298135 (69)31.2        *Age at diagnosis (years)*   0.002--- ⩽353219 (6)37.3   35--4419084 (28)30.7   45--54371201 (107)35.1   55--64376184 (84)32.9   65--74373137 (80)26.9   75--8418551 (38)21.6   ⩾853716 (13)30.2        *Disease presentation*   \<0.001\<0.001 Asymptomatic502302 (144)37.6   Symptomatic1013372 (198)26.9  [^1][^2][^3][^4] shows the crude and age-adjusted prevalence of FH+ women across the various categories. Family history was significantly associated with tumour size, ER, age at diagnosis and disease presentation. No significant association was found between family history and nodal involvement, PgR, Ki-67 status, grading or c-erb B2 levels ([Table 1](#tbl1){ref-type="table"}).

Associations with degree of familial relationship were investigated only for the variables significantly associated with a family history when a more general definition was used (tumour size, ER, age at diagnosis and disease presentation). Only age at diagnosis was significant ([χ]{.ul}^2^=36.0; *P*\<0.001): older women were more likely to have a first-degree relative (76.1% of those aged \>74 years had an affected first-degree relative *vs* 51.9% of those aged 45--74 and 33.0% of those aged \<45 years; data not shown).

DISCUSSION
==========

A positive family history is now an established risk factor for breast cancer, but few studies have focused on the characteristics of breast cancer in FH+ women. We have done so because physicians can rarely study genetic patterns in clinical practice, and must therefore rely on patient-supplied FH reports despite their possible inaccuracy ([Slattery and Kerber, 1993](#bib16){ref-type="other"}; [Eerola *et al*, 2000](#bib4){ref-type="other"}). Furthermore, some tumours will develop in relatives after the patient has been examined.

We have only considered first- and second-degree relatives, the percentages of which were similar to those reported in other studies ([Collaborative Group on Hormonal Factors in Breast Cancer, 2001](#bib3){ref-type="other"}). Our adjusted results suggest significant differences in FH+ tumours, which seem to be smaller, more often ER+, and more likely to be diagnosed at a younger age and at an asymptomatic stage. The published data are few and inconsistent, and usually not subject to multivariate analysis adjusted for age; in fact, only Kreiger about receptor status ([Kreiger *et al*, 1991](#bib9){ref-type="other"}) and Swede about c-erbB2 ([Swede *et al*, 2001](#bib17){ref-type="other"}) compared FH with clinical and pathological characteristics in a multivariate analysis adjusted for age as in this paper. Most have not found any significant difference in tumour size between FH+ and FH− patients ([Fukutomi *et al*, 1993](#bib5){ref-type="other"}; [Israeli *et al*, 1994](#bib8){ref-type="other"}; [Tsuchiya *et al*, 1998](#bib18){ref-type="other"}; [Russo *et al*, 2002](#bib15){ref-type="other"}), whereas Mohammed observed a trend ([Mohammed *et al*, 1998](#bib12){ref-type="other"}) and Colditz reported a higher percentage of T1 in women FH+ (60%) *vs* FH− (54%) ([Colditz *et al*, 1993](#bib2){ref-type="other"}). There were no significant differences in nodal involvement between our FH− and FH+ tumours. Some studies ([Fukutomi *et al*, 1993](#bib5){ref-type="other"}; [Mohammed *et al*, 1998](#bib12){ref-type="other"}) reported that FH+ patients were more likely to have tumours with fewer nodal metastasis, but others ([Ruder *et al*, 1988](#bib14){ref-type="other"}; [Israeli *et al*, 1994](#bib8){ref-type="other"}; [Tsuchiya *et al*, 1998](#bib18){ref-type="other"}; [Russo *et al*, 2002](#bib15){ref-type="other"}) found no significant difference.

Our univariate and multivariate analyses showed that FH+ tumours are more likely to be ER+, but there were no statistically significant differences in PgR, Ki-67 or grading. Some studies found that FH+ tumours are more likely to be ER− and PgR− ([Kreiger *et al*, 1991](#bib9){ref-type="other"}; [Huang *et al*, 2000](#bib7){ref-type="other"}), have a higher proliferation rate ([Marcus *et al*, 1994](#bib10){ref-type="other"}) and higher grading ([Mohammed *et al*, 1998](#bib12){ref-type="other"}), but none of the others found any differences ([Fukutomi *et al*, 1993](#bib5){ref-type="other"}; [Israeli *et al*, 1994](#bib8){ref-type="other"}; [Tsuchiya *et al*, 1998](#bib18){ref-type="other"}; [Russo *et al*, 2002](#bib15){ref-type="other"}).

In agreement with others ([Fukutomi *et al*, 1993](#bib5){ref-type="other"}; [Swede *et al*, 2001](#bib17){ref-type="other"}), we did not find any differences in relation to the more recent c-erbB2 marker.

Our FH+ tumours were more frequently diagnosed in an asymptomatic phase than the FH− tumours. This is probably due to the greater sensitisation induced by having one or more affected relatives, which encourages asymptomatic women to undergo diagnostic investigations; our data are similar to those of others ([Colditz *et al*, 1993](#bib2){ref-type="other"}; [Murabito *et al*, 2001](#bib13){ref-type="other"}) who have observed that FH+ women undergo more mammographies.

Our FH+ patients were younger at diagnosis, which confirms some previous data ([Israeli *et al*, 1994](#bib8){ref-type="other"}), but not others ([McCredie *et al*, 1997](#bib11){ref-type="other"}; [Tsuchiya *et al*, 1998](#bib18){ref-type="other"}; [Russo *et al*, 2002](#bib15){ref-type="other"}).

In conclusion, FH+ seems to be associated with an asymptomatic diagnosis (and therefore smaller and ER+ tumours), possibly because of the more intensive use of mammography or differences in biological behaviour. FH+ patients are younger, although it is not clear as to whether this reflects a truly earlier disease onset or an earlier diagnosis due to the more intensive use of mammography.

[^1]: ER=oestrogen receptors; PgR=progesteron receptors.

[^2]: No family history of breast cancer.

[^3]: Family history of breast cancer.

[^4]: *P*-value adjusted for age at diagnosis.
